BioSpace News Archive

Policy

HHS Halts FDA Fetal-Tissue Contract, Plans to Conduct Sweeping Review

The Trump administration has launched a sweeping federal review on the use of fetal tissue that includes the cancellation of a contract between a supplier and researchers at the U.S. Food and Drug Administration.

September 26, 2018
·
2 min read
·
Alex Keown
Business

Thomson Reuters Report: 10 Biopharma Companies in Top 50 Most Diverse List

Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.

September 26, 2018
·
5 min read
·
Mark Terry
Business

Bluechiip Ltd (ASX:BCT) Annual Report to Shareholders

Bluechiip Ltd (ASX:BCT) provides the Company’s Annual Report to shareholders.

September 26, 2018
·
2 min read
BioForest

VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy

Breakthrough Research to be Presented at the 2018 World Conference on Lung Cancer

September 26, 2018
·
9 min read
Drug Development

Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).

September 26, 2018
·
11 min read
Business

2018 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €238M AND SIGNIFICANT ADVANCES IN THE CLINICAL DEVELOPMENT OF ELAFIBRANOR

Completion of enrollment of approx. 1000-patient study cohort for Phase 3 RESOLVE-IT study, on the basis of which conditional marketing approval for elafibranor in NASH could be obtained in 2020. Interim data readout expected by end of 2019.

September 26, 2018
·
26 min read
Policy

Accord Healthcare’s Pelgraz® Approved by EMA

For the first time in Europe, a pegylated G-CSF biosimilar pegfilgrastim will be available to patients for the treatment of neutropenia

September 26, 2018
·
2 min read
Biotech Bay

Holistic digital health for asthma and COPD patients using the Hailie™ Solution

Adherium’s range of Hailie™ sensors and software platform fits into patients’ daily routines and aids in effective medicine management for asthma and COPD, enabling patients, parents and caregivers to worry less about the condition.

September 26, 2018
·
1 min read
Deals

Brooks Automation Moves Further into Life Sciences with $450 Million Deal for Genewiz Group

Automation and cryogenics specialist Brooks Automation Inc. will increase its toehold in the life sciences industry with a $450 million all-cash acquisition of New Jersey-based Genewiz Group, a genomic services group.

September 26, 2018
·
2 min read
·
Alex Keown
Genetown

Lyra Therapeutics Raises $29.5 Million for New Ear-Nose-Throat Drug Delivery System

Watertown, Massachusetts-based Lyra Therapeutics closed a Series B financing worth $29.5 million. Its lead compound is LYR-210, which the company plans to take into a Phase II clinical trial for chronic rhinosinusitis

September 26, 2018
·
3 min read
·
Mark Terry